Technology Platform

GentleFectTM: Peptide LLPS-powered Precision Nucleic-acid Delivery Platform

图片22221.png

Genda-Bio’s next-gen platform couples AI design, high-throughput primary-cell screening, and peptide-based, non-viral delivery for nucleic acids.

 

Bridging Research and Industry: Delivering Efficient & Harmless Solutions for Basic Research and cell therapy Development

Nucleic acid delivery remains the critical bottleneck in gene function studies and therapeutic applications. Genda-Bio leverages proprietary peptide engineering to harness the innate biocompatibility and phase separation properties of natural peptides, pioneering the GentleFectTM platform. Inspired by native cellular mechanisms, it surpasses liposomal and viral vectors, enabling high-efficiency, low-toxicity delivery of exogenous nucleic acids and offering a new solution for transfecting primary and hard-to-transfect cells.


Applications: End-to-End Solutions for Bench to Bedside

l Basic Research: CRISPR editing, gene modulation, and pathway studies in all cell types; especially in primary-cell validation and hard-to-transfect tumor models—trusted by 1,500+ teams.

l Cell therapy: Non-viral nucleic-acid delivery for Stem cells and T cells with minimal toxicity, sustaining cell viability; adopted in multiple pre-clinical programs.


Presentation: High Transfection Positivity and Cell Viability (Human Primary Mesenchymal Stem Cells)

1753751818674353.jpg

                                                       99% GFP mRNA positive rate                                                                             Maintain normal proliferation

1234.jpg

99% GFP mRNA positive rate

1235e.jpg

Maintain normal proliferation